Relay Therapeutics stock holds near its Nasdaq quote

Published on 09/22/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Relay Therapeutics stock was quoted at a dated Nasdaq level, while its latest reported period supplies revenue and earnings context. The pipeline remains central.

RLAY, US76034L1026, Illustration mit AI erstellt.

Relay Therapeutics (ISIN US76034L1026) stock was quoted on Nasdaq at a dated market level, with the company also carrying a latest reported period of revenue and earnings data. The market figures and reporting-period data frame the investment case without mixing venues or currencies.

Nasdaq data set the reference

The reference quotation for Relay Therapeutics is Nasdaq in USD. The dated price, prior close, daily percentage change, 52-week range, market capitalization and volume belong to the same market-data snapshot and should be read as a single time-stamped set.

That distinction matters for a US-listed biotechnology company because a German secondary quotation would not provide the primary reference price. The comparison is therefore limited to Nasdaq data and the prior close of the same venue.

Reported figures anchor valuation

Relay Therapeutics latest reported revenue, earnings and margin figures are period-specific rather than interchangeable with the publication date. The relevant reporting period, quarter or fiscal year is the basis for assessing whether the operating trend improved or weakened.

For investors, the most useful comparison is the change against the immediately preceding comparable period. Revenue growth or contraction, earnings per share and cash use provide a more precise frame than a general description of biotechnology sentiment.

Pipeline remains the key variable

Relay Therapeutics stock remains tied to clinical execution because pipeline progress can alter the value assigned to future products more quickly than current revenue. The next dated company event, when explicitly scheduled, is the next checkpoint for operating information.

Risk is concentrated in development timing, clinical outcomes and financing needs. Those factors can affect valuation even when the Nasdaq quotation changes only modestly over a single session.

Nasdaq quotation defines the close

Relay Therapeutics stock is assessed here using its primary Nasdaq quotation in USD and the matching market-data date. The latest reporting-period figures provide the fundamental comparison, while the pipeline calendar supplies the next measurable company checkpoint.